Gefitinib-ble on this full pub.

We already brought you prelim results of the ADJUVANT trial, but now we’re bringing you the full length manuscript. As a reminder, in patients with resected stage II-IIIA EGFR-mutant NSCLC, adjuvant gefitinib (EGFR-TKI) significantly improved disease-free survival to 29 months from 18 months with standard vinorelbine and cisplatin. The kicker is that these patients received gefitinib for two whole years. And then what happened? Just like in the RADIANT trial, the Kaplan-Meier curves plummeted after stopping the EGFR-TKI. The problem is these EGFR-TKIs work wonders at suppressing--but not curing--occult disease. This brings up two questions: how long is long enough for EGFR-TKIs, and with what other therapies can it be combined? Notwithstanding the elusive cure, gefitinib has earned its title as the new standard for resected EGFR-mutant NSCLC...though only time will tell how it stacks up against (or with?) adjuvant immunotherapies.